MA Fischl, DD Richman, N Hansen, AC … - Annals of Internal …, 1990 - Am Coll Physicians Annals. Search Annals : Advanced search. ... Cited by 430 - Related articles - All 2 versions
PA Volberding, SW Lagakos, MA Koch, C … - The New England …, 1990 - nejm.highwire.org Zidovudine (AZT) is a potent inhibitor of the replication of the human immunodeficiency virus
(HIV), and it has been shown to improve survival in advanced HIV disease. We conducted a
randomized, double-blind trial in adults with asymptomatic HIV infection who had CD4+ ... Cited by 682 - Related articles - All 5 versions
JD Hamilton, PM Hartigan, MS Simberkoff - J Med, 1992 - rethinkingaids.com Vol.326 Na 7 EARLY VS. 1.ЛТК ZIDOVUDINE IK HIV INFECTION HAMILTON FT Al. 43<) group
and 7 in the late-therapy group) who did not mct't the eligibility criteria in minor way». The:
exclu- sion of thrse 11 patients does not aliei' lhe conclusions of the study. The patients ... Cited by 239 - Related articles - All 8 versions
MA Fischl, DD Richman, MH Grieco, MS … - New England Journal …, 1987 - content.nejm.org We conducted a double-blind, placebo-controlled trial of the efficacy of oral azidothymidine
(AZT) in 282 patients with the acquired immunodeficiency syndrome (AIDS) manifested by Pneumocystis
carinii pneumonia alone, or with advanced AIDS-related complex. The subjects were ... Cited by 1405 - Related articles - All 6 versions
JO Kahn, SW Lagakos, DD Richman, A Cross, … - New England Journal …, 1992 - content.nejm.org BACKGROUND. Although zidovudine is effective in patients with human immunodeficiency virus
(HIV) infection, its efficacy may decline with prolonged use. Didanosine is another inhibitor of
HIV reverse transcriptase. We evaluated the effectiveness of changing anti-HIV treatment ... Cited by 274 - Related articles - All 4 versions
MA Fischl, CB Parker, C Pettinelli, M Wulfsohn … - New England Journal …, 1990 - content.nejm.org BACKGROUND. The initially tested dose of zidovudine for the treatment of patients with advanced
disease caused by the human immunodeficiency virus type 1 (HIV) was 1500 mg. Although this
dose is effective, it is associated with substantial toxicity. METHODS. To evaluate the ... Cited by 207 - Related articles - All 4 versions
[CITATION] Zidovudine in asymptomatic human immunodeficiency virus infection
- ►uni-muenchen.de [PDF] DA Cooper, JM Gatell, S Kroon, N Clumeck, J … - New England Journal …, 1993 - content.nejm.org Methods In a double-blind, placebo-controlled trial, 993 patients with asymptomatic HIV infection
and CD4+ cell counts above 400 per cubic millimeter were randomly assigned to receive zidovudine
(500 mg twice daily) or placebo for three years. The primary end point was progression of ... Cited by 176 - Related articles - BL Direct - All 6 versions
MA Fischl, DD Richman, DM Causey, MH Grieco, Y … - JAMA, 1989 - Am Med Assoc We examined the long-term safety and efficacy of zidovudine therapy in 229 subjects with acquired
immunodeficiency syndrome (AIDS) and AIDS-related complex who previously participated in
a placebo-controlled study of zidovudine. One hundred two placebo recipients (delayed ... Cited by 160 - Related articles - All 3 versions
TC Meng, MA Fischl, AM Boota, SA Spector, … - Annals of internal …, 1992 - Am Coll Physicians Objective: To evaluate the safety and immunologic and antiviral effects of combination therapy
with zidovudine and dideoxycytidine (ddC) in patients with advanced human immunodeficiency
virus type 1 (HIV) infection. ... Design: A phase I/II open-label, dose-ranging study. Cited by 127 - Related articles - All 3 versions
